

NEWS RELEASE

nDatalyze announces YMI mHealth application beta is now online.

Calgary, Alberta – March 8, 2022

For Immediate Release – nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT, OTCQB:NDATF) is pleased to announce that it's YMI mHealth application beta is now online through the Corporation's website at https://www.ymihealth.com/ (copy/paste if the link doesn't work). During the beta test period access is limited and persons wanting to become beta testers should contact the Corporation for eligibility.

James Durward, President, states: "With mental health now "front and centre" in today's society, we believe YMI is the right product at the right time. Today's beta release incorporates live, real-time Anxiety, Depression, PTSD and OCD predicted probabilities, four of today's most common mental conditions. This advanced product has been made possible by our proprietary Reference Database and supervised machine-learning algorithms. The YMI interface now features numerous additions based on feedback from our recent third-party marketing study and the beta release is designed to allow further refinement of demographics, "look&feel" and pricing. YMI beta is being made available for free to a limited number of demographically-defined participants and we expect to open YMI to the general public in the near future."

The Corporation further reports that it expects to incorporate the final three conditions of BiPolar, Alcoholism and Personality disorders during or shortly after beta completion.

About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation's proprietary Reference Database consisting of >1200 biometric records complete with "same-time-of-day" EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.

FOR FURTHER INFORMATION, PLEASE CONTACT:

nDatalyze Corp.

James Durward, President and CEO

Telephone: (403) 689-3901

Email: jimd@ndatalyze.com Website: www.ndatalyze.com

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.